Integer Holdings Corp (ITGR)
121.24
-0.41
(-0.34%)
USD |
NYSE |
May 31, 16:00
121.23
-0.01
(-0.01%)
Pre-Market: 20:00
Integer Holdings SG&A Expense (Annual): 175.62M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 175.62M |
December 31, 2022 | 160.58M |
December 31, 2021 | 141.42M |
December 31, 2020 | 109.01M |
December 31, 2019 | 138.70M |
December 31, 2018 | 142.44M |
December 31, 2017 | 143.07M |
December 31, 2016 | 136.44M |
December 31, 2015 | 102.53M |
December 31, 2014 | 90.60M |
December 31, 2013 | 88.11M |
December 31, 2012 | 80.99M |
December 31, 2011 | 72.55M |
Date | Value |
---|---|
December 31, 2010 | 64.51M |
December 31, 2009 | 70.29M |
December 31, 2008 | 72.63M |
December 31, 2007 | 44.67M |
December 31, 2006 | 38.78M |
December 31, 2005 | 50.10M |
December 31, 2004 | 31.30M |
December 31, 2003 | 31.42M |
December 31, 2002 | 24.37M |
December 31, 2001 | 18.17M |
December 31, 2000 | 11.47M |
December 31, 1999 | 9.88M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
109.01M
Minimum
2020
175.62M
Maximum
2023
145.06M
Average
141.42M
Median
2021
SG&A Expense (Annual) Benchmarks
Boston Scientific Corp | 5.19B |
Abbott Laboratories | 10.95B |
ResMed Inc | 874.00M |
Glaukos Corp | 224.07M |
Perspective Therapeutics Inc | 21.06M |